

Original citation:

Lévi, Francis A., Dugué, Pierre-Antoine, Innominato, Pasquale F., Karaboué, Abdoulaye, Dispersyn, Garance, Parganiha, Arti, Giacchetti, Sylvie, Moreau, Thierry, Focan, Christian, Waterhouse, Jim and Spiegel, David. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. *Chronobiology International*, 31 (8). pp. 891-900.

Permanent WRAP URL:

<http://wrap.warwick.ac.uk/85076>

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:


"This is an Accepted Manuscript of an article published by Taylor & Francis in *International Journal of Social Research Methodology* on 13/06/2013 available online:

<http://dx.doi.org/10.3109/07420528.2014.924523>

A note on versions:

The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL' above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk



Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival

Journal:	<i>Chronobiology International</i>
Manuscript ID:	LCBI-2014-0132.R1
Manuscript Type:	Original Reports
Date Submitted by the Author:	n/a
Complete List of Authors:	Lévi, Francis; INSERM, UMRS 776 « Biological Rhythms and Cancers » , ; Université Paris Sud 11, UMR-S0776, ; Assistance Publique - Hôpitaux de Paris, Chronotherapy Unit, Department of Oncology, Paul Brousse Hospital, , Dugué, Pierre-Antoine; INSERM, UMRS 776 « Biological Rhythms and Cancers » , Innominato, Pasquale; INSERM, UMRS 776 « Biological Rhythms and Cancers » , ; Université Paris Sud 11, UMR-S0776, , ; Assistance Publique - Hôpitaux de Paris, Chronotherapy Unit, Department of Oncology, Paul Brousse Hospital, , Karaboué, Abdoulaye; INSERM, UMRS 776 « Biological Rhythms and Cancers » , ; Université Paris Sud 11, UMR-S0776, , Dispersyn, Garance; INSERM, UMRS 776 « Biological Rhythms and Cancers » , ; Université Paris Sud 11, UMR-S0776, , Parganiha, Artj; INSERM, UMRS 776 « Biological Rhythms and Cancers » , ; Université Paris Sud 11, UMR-S0776 , ; Chronobiology Laboratory, School of Life Sciences, Pt. Ravishankar Shukla University , Giacchetti, Sylvie; INSERM, UMRS 776 « Biological Rhythms and Cancers » , ; Université Paris Sud 11, UMR-S0776, , ; Assistance Publique - Hôpitaux de Paris, Chronotherapy Unit, Department of Oncology, Paul Brousse Hospital, , Moreau, Thierry; INSERM U1018, Centre d'Epidémiologie et de Santé Publique, Paul Brousse Hospital, Focan, Christian; Department of Oncology, Centre Hospitalier Chrétien, Clinique Saint-Joseph, Waterhouse, James; Liverpool John Moores University, Spiegel, David; Stanford School of Medicine, Center of Stress and Health
Keywords:	Biomarkers , cancer, circadian clock, rest-activity rhythm, survival

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

For Peer Review Only

Chronobiology International by F LEVI 02/05/2014

1
2
3
4
5 **Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients**
6
7 **survival**
8
9

10
11 Francis Lévi ^{a,b,c}, Pierre-Antoine Dugué ^a, Pasquale Innominato ^{a,b,c}, Abdoulaye Karaboué ^{a,b},
12 Garance Dispersyn ^{a,b}, Arti Parganiha ^{a,b,d}, Sylvie Giacchetti ^{a,b,c}, Thierry Moreau ^e, Christian
13 Focan ^f, Jim Waterhouse ^g, and David Spiegel ^h, on behalf of the ARTBC Chronotherapy
14 Group.
15
16
17
18
19

20
21 **AFFILIATIONS**
22

23
24 ^a INSERM, UMRS 776 « Biological Rhythms and Cancers », Campus CNRS, 7 rue Guy
25 Môquet, 94801 Villejuif Cedex, France.
26
27

28
29 ^b Université Paris Sud 11, UMR-S0776, Orsay, France
30

31
32 ^c Assistance Publique - Hôpitaux de Paris, Chronotherapy Unit, Department of Oncology,
33 Paul Brousse Hospital, Villejuif, France
34
35

36
37 ^d Chronobiology Laboratory, School of Life Sciences, Pt. Ravishankar Shukla University,
38 Raipur - 492 010, India.
39

40
41 ^e INSERM U1018, Centre d'Epidémiologie et de Santé Publique, Paul Brousse Hospital,
42 94800 Villejuif, France.
43
44

45
46 ^f Department of Oncology, Centre Hospitalier Chrétien, Clinique Saint-Joseph, Liège,
47 Belgium.
48
49

50
51 ^g John Moores University, Liverpool, United Kingdom.
52

53
54 ^h Stanford University School of Medicine, Department of Psychiatry, Stanford, CA, USA.
55
56

Chronobiology International by F LEVI 02/05/2014

1
2
3
4
5 **Running title**
6

7 Rest-activity rhythm as a predictor of survival
8
9

10 **Key words**
11

12 Biomarkers, cancer, circadian clock, rest-activity rhythm, survival
13
14

15 **Corresponding author:** Dr Francis Lévi, INSERM UMRS 776, « Rythmes biologiques et
16 cancers », Campus CNRS , 7 rue Guy Môquet, 94801 Villejuif Cedex, France.
17
18

19
20 Mail : francis.levi@inserm.fr
21
22

23 Phone : +33149583483 or 3481, Fax : +33149583459
24
25

26 **Funding**
27

28 Association Internationale pour la Recherche sur le Temps Biologique et la Chronothérapie
29 (ARTBC International), Paul Brousse hospital, Villejuif, France ; European Union through
30 the 7th Framework Programme project In-CASA (Contract CIP 250505).
31
32
33

34
35
36 D. Spiegel benefitted from a Fulbright senior fellowship.
37

38 A. Parganiha had a postdoctoral fellowship from Paris Sud University.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

ABSTRACT

The disruption of the Circadian Timing System (CTS), which rhythmically controls cellular metabolism and proliferation, accelerated experimental cancer progression. A measure of CTS function in cancer patients could thus provide novel prediction information for outcomes, and help identify novel specific therapies. The rest-activity circadian rhythm is a reliable and non invasive CTS biomarker, which was monitored using a wrist watch accelerometer for 2 days in 436 patients with metastatic colorectal cancer. The relative percentage of activity in-bed versus out-of-bed (I<O) constituted the tested CTS measure, whose prognostic value for overall survival (OS) and progression-free survival (PFS) was determined in a pooled analysis of three patient cohorts with different treatment exposures. Median OS was 21.6 months [17.8-25.5] for patients with I<O above the median value of 97.5% as compared to 11.9 months [10.4-13.3] for those with a lower I<O (Logrank $p<0.001$). Multivariate analyses retained continuous I<O as a joint predictor of both OS and PFS, with respective Hazard Ratios (HR) of 0.954 ($p<0.001$) and 0.970 ($p<0.001$) for each 1% increase in I<O. HRs had similar values in all the patient subgroups tested. The circadian physiology biomarker I<O constitutes a robust and independent quantitative predictor of cancer patient outcomes, that can be easily and cost-effectively measured during daily living. Interventional studies involving 24-h schedules of clock-targeted drugs, light intensity, exercise and/or meals are needed for testing the relevance of circadian synchronization for the survival of patients with disrupted rhythms.

Chronobiology International by F LEVI 02/05/2014

INTRODUCTION

Circadian rhythms are potential biomarkers related to health and diseases. These rhythms are generated at single cell level by a molecular clock involving at least 15 specific genes (Dibner et al., 2010). The cellular clocks are coordinated by the suprachiasmatic nuclei (SCN) in the hypothalamus, a pacemaker that further adjusts the circadian rhythms to the environmental day-night cycles (Dibner et al., 2010). Experimental data further show that the network of molecular clocks that constitute the Circadian Timing System (CTS) is a control point for tumor progression. Thus cancer progression was accelerated two- to three-fold in tumor-bearing mice whose rest-activity rhythm was suppressed as a result of SCN ablation or chronic 'jet lag' (Fu et al., 2002; Filipski et al., 2002). Conversely CTS amplification through programmed daily meal timing halved experimental cancer growth in mice (Wu et al., 2004, Li et al., 2010). Here we investigated the clinical relevance of such preclinical findings in a large sample of cancer patients, using non invasive technology.

The rest-activity rhythm constitutes a clinically relevant circadian biomarker, since it is amenable to non-invasive monitoring with a wrist watch accelerometer (Mormont et al., 2000). The quest for circadian biomarkers of human health is further supported by the demonstration of an increased risk of cancer in shift workers exposed to occupational schedules that disrupt circadian rhythms (IARC-Working-Group, 2010). The human CTS is synchronized by environmental light-dark alternation, as well as by socio-professional routine and meal timing, whose iterative and sustained alterations disrupt the CTS (Levi et al., 2010). Such disruption has been documented using several parameters derived from wrist actimetry monitoring (Mormont et al., 2000; Ancoli-Israel et al., 2003; Berger et al., 2008). Several such devices have been approved for human use, yet their specific technical design and the time series analyses methods that are used can influence the parameter values that are obtained. Using the Minimotion logger actimeter®, we first revealed the clinical relevance of the

Chronobiology International by F LEVI 02/05/2014

1
2 dichotomy index $I<O$, a measure of the percentage of in-bed activity counts that are less than
3
4 the median of out-of-bed counts (Mormont et al., 2000; Minors et al., 1996). Thus, in two
5
6 previous cohort studies, $I<O$ provided consistent prognostic information on the survival of
7
8 patients with metastatic colorectal cancer (Mormont et al., 2000; Innominato et al., 2009a).
9
10 Cohort I was a single institution study that included 192 consecutive patients mostly receiving
11
12 chronomodulated 5-Fluorouracil-Leucovorin-Oxaliplatin chemotherapy after failure of a first
13
14 treatment protocol (Mormont et al., 2000). Cohort II consisted of 130 chemo-naïve patients
15
16 receiving chronomodulated or conventional delivery of the same 3-drug protocol within a
17
18 randomized international Phase III trial (Innominato et al., 2009a). Such easily measurable
19
20 circadian biomarkers that predict patient survival outcome have the potential for improving
21
22 cancer care through the assessment of prognosis, the prediction of response to specific
23
24 treatments, as well as the identification of novel circadian therapeutics (Buyse et al., 2010).
25
26
27
28

29 Here, we first aimed at confirming the prognostic value of $I<O$ as a circadian biomarker
30
31 within a third cohort of 142 patients with metastatic colorectal cancer. These patients then
32
33 received salvage multidrug chronotherapy as part of their routine oncology management after
34
35 failure of chemotherapy for a majority of them. We then determined the prognostic value of
36
37 $I<O$ in a pooled analysis involving the 436 patients with metastatic colorectal cancer, accrued
38
39 in the three aforementioned cohorts. The primary aim of such pooled analysis was to examine
40
41 rest-activity rhythm as a circadian biomarker for the prediction of survival and progression-
42
43 free outcomes in patients with metastatic colorectal cancer, with adequate statistical power. A
44
45 secondary aim was to explore the relations between the rest-activity circadian rhythm and
46
47 outcomes in the main patient subgroups. This analysis was made possible by the large sample
48
49 size of the pooled dataset. Such results were required before a broad routine implementation
50
51 of this biomarker in the framework of personalized patient-centered cancer chronotherapy.
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

MATERIALS AND METHODS

Patient cohorts and treatment regimens

The pooled analysis involved 436 patients with metastatic colorectal cancer who had been enrolled in any of the three cohorts that prospectively investigated the relations between rest-activity rhythm and patient outcomes from April 1994 to November 2006. The patients in these cohorts were subsets of clinical studies (Cohorts I and II) or had actimetry assessment as part of their routine chronotherapy management (Figure 1). Entry criteria in each of the three cohort studies included histological proof of colorectal cancer, measurable metastatic disease, WHO Performance Status less than 3, and signed written informed consent. Eligible patients had a physical examination, Computed Tomography (CT) scan of the thorax, abdomen and pelvis, a complete blood count, and serum chemistry including CEA and CA19-9. All the patients had rest-activity recorded with a wrist watch “Mini-motion Logger” for a minimum of 48 h up to 7 days. The patients subsequently received at least one course of conventional or circadian-based chemotherapy (chronotherapy) involving oxaliplatin (O), irinotecan (I) or both, eventually combined with 5-fluorouracil (F) and Leucovorin (L) (Levi et al., 1997; Gholam et al., 2006). ChronoFL consisted in four consecutive daily chronomodulated infusions of 5-fluorouracil (cumulative dose per course, 2800-3200 mg/m²) and leucovorin (1200 mg/m²) from 22:15 to 9:45, with peak delivery rate at 4:00 at night every 2 weeks (Giacchetti et al., 2000). ChronoFLO involved the addition of four daily chronomodulated oxaliplatin infusions from 10:15 to 21:45 with peak delivery rate at 16:00 (cumulative dose, 85-100 mg/m²) (Giacchetti et al., 2006). For chronoIFL, irinotecan (180 mg/m²) was infused from 02:00 to 08:00 with peak delivery at 05:00 on day 1, then followed by chronoFL (garufi et al., 2006). The chronoIFLO schedule combined day1 chronomodulated irinotecan (180mg/m²) with day2-5 chronoFLO (5-fluorouracil, 2800 mg/m², leucovorin, 1200 mg/m², oxaliplatin, 85 mg/m²) every 3 weeks (Gholam et al., 2006).

Chronobiology International by F LEVI 02/05/2014

1
2
3
4
5 The characteristics of the patients in Cohorts I and II were previously reported (Mormont et
6 al., 2000; Innominato et al., 2009a). The majority of the 142 patients in Cohort III (69%) had
7 failed on prior chemotherapy for metastatic disease, while this was the case for none of the
8 patients in Cohort II. Fifty-five percent and 33% of the patients in Cohort III had received
9 prior oxaliplatin and irinotecan respectively, before rest-activity rhythm assessment. In
10 contrast, these agents had been respectively administered to 1.8% and 5.4% of the patients in
11 Cohort I (Mormont et al., 2000). The main chemotherapy protocols given after rest-activity
12 assessment differed among the three cohorts. Patients in Cohort I received FL or FLO
13 chronotherapy as first or second line chemotherapy (Giacchetti et al., 2000; Levi et al., 2007;
14 Curé et al., 2002). Patients in Cohort II received first line chronoFLO or FOLFOX for
15 metastatic disease (Innominato et al., 2009a; Giacchetti et al., 2006). Irinotecan-based
16 chemotherapy was administered to 39.4% of the patients in Cohort III, and in none of the
17 patients in either Cohort I or II.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 *Efficacy endpoints*

38
39 Patients were followed for up to 10 years after actimetry recording. Response was assessed
40 every third or fourth treatment course and defined according to WHO criteria (Jaffe, 2006).
41 Independent radiology assessment was conducted for patients considered responders by the
42 investigator. Patients were taken off the post actimetry treatment protocol as a result of
43 progressive disease, lack of full recovery from severe toxicity, or complete surgical resection
44 of metastases. Overall survival (OS) was defined as the time from first day of actimetry
45 recording (day 0) to death or last time known alive. Patients who discontinued therapy for
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

1
2 reasons other than death or progression were censored at the drop out date. Progression-free
3
4 survival (PFS) was also computed from day 0 to progression or death.
5
6
7
8
9

10 11 12 *Rest-activity rhythm monitoring* 13

14 To assess individual circadian rest-activity rhythm, a Mini-Motionlogger actigraph
15 (Ambulatory Monitoring Inc., USA) was used. The actigraph looks similar to a watch and is
16 worn on the non-dominant wrist. It contains a piezoelectric linear accelerometer to detect
17 wrist movements and a memory chip for data storage. The time interval for the recording and
18 count of activity level was 1 min. The actigraph was worn for at least 48 h continuously
19 before the beginning of the first course of a new chemotherapy protocol.
20
21
22
23
24
25
26
27

28 29 *Actimetry time series analyses* 30

31 All actimetry time series were analyzed using a specific program (Action 4 version 1.10;
32 Ambulatory Monitoring Inc., USA). The dichotomy index (I<O) was computed as the percent of
33 time of activity in-bed, that is below the median level of activity out-of-bed (Mormont et al.,
34 2000; Minors et al., 1996). Thus, the primary measure, I<O, essentially assessed the reduction in
35 physical activity while in-bed (I) compared to that when out-of-bed (O). A normal dichotomy
36 index is one approaching 100%, indicating restful sleep and regular daily activity. The I<O
37 measure is based upon 24 h of actimetry readings. Visual inspection of each day's data indicated
38 the approximate times of retiring and rising, based on sustained falls and rises in the activity
39 counts, respectively. Activity counts during one hour before and one hour after each of these two
40 times were ignored. This meant that a total of 20 h data per 24 h was considered, with a
41 reasonable certainty that the data spans that were analysed indeed consisted of a section
42 associated with attempted sleep (I, in bed) and another section associated with being awake (O,
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

1
2 out of bed). Daytime naps were included in the “awake” section. The median value of each of the
3
4 two sections was then calculated, so that no assumption on data normalcy of distribution was
5
6 required. I<O would be expected to approach 100% as a subject’s dichotomy (between in-bed
7
8 inactivity and out-of bed activity) increased. Values of I<O in healthy controls are rarely <98% (
9
10 Minors et al., 1996). Lower values of I<O can be due to lower values of O and/or higher values
11
12 of I. In practice, O (the median of all waking activity) rarely decreases sufficiently for it to exert
13
14 a large influence on the index; it is usually a rise in activity counts during the time of attempted
15
16 sleep that is the dominant factor in causing the I<O index to drop (Innominato et al., 2009a).
17
18 Records examples and corresponding I<O values are shown in Figure 2. Neither the visual
19
20 pattern of rest-activity nor the computed parameters were known by the clinician who prescribed
21
22 the treatment protocol or took charge in patient management.
23
24
25

26 27 *Statistical methods*

28
29 Median and range were computed for I<O. The relations between patient characteristics and
30
31 I<O upon study entry were tested using Kruskal-Wallis non-parametric tests for categorical
32
33 variables and Pearson correlation for continuous variables. Median and interquartile range
34
35 (IQR) were computed according to performance status, sex, number of metastatic sites and
36
37 number of chemotherapy lines before actimetry measurements.
38
39

40
41 For illustrating the prognostic role of I<O on OS and PFS, patients were split in two groups
42
43 according to I<O value either above or below I<O median value, and the corresponding
44
45 Kaplan-Meier survival curves were plotted. Logrank tests were performed for testing equality
46
47 of survival functions. Multivariate analyses were performed using Cox proportional hazard
48
49 models to investigate the effect of I<O on OS and PFS, in each patient cohort and in the
50
51 whole study population. Variables with $p < 0.10$ according to univariate analysis were selected
52
53 (\dagger in Table 1), and retained in the multivariate model using $p < 0.05$ for the Wald test , using
54
55 the forward stepwise selection procedure. In the pooled analysis, OS and PFS were analyzed
56
57
58

9

Chronobiology International by F LEVI 02/05/2014

1 following stratification according to cohort, in order to account for differences in patient
2 demographics, advancement of metastatic disease and treatment protocols after actimetry.
3
4 These stratified Cox models allowed the underlying hazard function to vary across the 3
5 cohorts. For each model, I<O was used as a continuous variable, and the proportional hazards
6 assumption was evaluated by plotting the martingale residuals. Forest plots were drawn to
7 illustrate the effect of I<O within different patient subgroups and to visualize the adjusted
8 hazard ratios estimated in the multivariate Cox models and representing the effect of I<O on
9 OS and PFS in each patient cohort and in the whole study population. All analyses were
10 performed using R 2.15.2 and PASW Statistics 20 software (SPSS, Chicago, IL, USA).
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 RESULTS

26
27 The circadian patterns in rest-activity differed largely among individual patients with similar
28 characteristics. Such inter-patient differences appeared to be adequately recapitulated in the
29 computation of I<O (Figure 2). In the pooled patient population, I<O varied according to
30 performance status, ranging from a median value of 98.2 [IQR: 95.4 to 99.3] for PS=0, to 96.5
31 [93.1 to 99.0] for PS=1, and 91.5 [79.1 to 97.0] for PS ≥ 2 , with statistically significant
32 differences in distribution (p from Kruskal-Wallis test <0.001). Median I<O was 97.1 [93.5
33 to 99.0] in males, and 98.0 [94.1 to 99.4] in females (p = 0.04). The I<O distribution also
34 varied according to number of metastatic sites, the medians ranging from 99.4 [98.2 to 99.9]
35 in the patients without any detected metastasis, to 97.9 [94.1 to 99.2] in those with one
36 metastatic site, and 97.1 [92.7 to 99.0] in the patients with ≥ 2 metastatic sites (p = 0.03).
37 Median I<O values were similar in chemotherapy-naïve patients (97.5 [93.5 to 99.2]), as well
38 as in patients previously treated with one (97.7 [94.5 to 99.1]) or ≥ 2 chemotherapy protocols
39 (97.2 [92.9 to 99.2]) (Kruskal-Wallis, p = 0.84).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cohort III

The study enrolled 142 patients, who signed an informed consent form. Patients had poor prognosis disease as indicated by the administration of one to three conventional chemotherapy protocols to 69% of the patients, prior surgery for metastases among 41.5% of the patients, and prior administration of oxaliplatin and/or irinotecan for 55% and 33.1% of the patients respectively (Table 1). I<O ranged from 63.2 to 100%, with a median value of 98.3%. The patients subsequently received chronoFLO (47.9%), irinotecan-based combination chronotherapy (39.4%), or another schedule (12.7%).

Patients with I<O above its median value had a better overall survival than those with a lower I<O ($p=0.006$), with respective median survival of 23.3 months [95% Confidence Interval, 13.6 to 33.0] versus 14.1 months [95% C.I., 9.1 to 19.2] (curves not shown). Similarly, median PFS was 7.4 months [95% C.I., 5.4 to 9.5] in the patients with I<O above 98.3% as compared to 5.1 months [95% C.I., 2.8 to 7.3] in those with lower I<O value (curves not shown). However, the PFS curves did not differ significantly according to median of I<O ($p=0.068$). Multivariate analysis revealed continuous I<O as an independent prognostic factor for overall survival, along with performance status, number of metastatic sites, number of prior chemotherapy protocols, and subsequent surgery for metastases (results not shown). The adjusted hazard ratio corresponding to a one percent increase of I<O was 0.953 [95% C.I., 0.924 to 0.984] ($p=0.003$).

POOLED PATIENT POPULATION

Patient characteristics

Chronobiology International by F LEVI 02/05/2014

1
2 The updated patient data from the patients in Cohorts I and II were pooled with the patient
3 data from Cohort III (Table 1). Overall, a total of 436 patients with metastatic colorectal
4 cancer had adequate longitudinal assessment of their rest-activity rhythm for time series
5 analysis (Figure 1). The pooled sample consisted of 37.4% women and 62.6% men from four
6 countries. Fifty-one percent of the patients had two or more metastatic sites. Prior
7 chemotherapy for metastatic disease had been administered to 45.4% of the patients.
8 Following rest-activity rhythm assessment, chemotherapy was administered as a conventional
9 modality for 71 patients (16.4%) (Giacchetti et al., 2000, Giacchetti et al., 2006) or as
10 chronotherapy for 360 patients (82.6%). Chronotherapy included chronoFLO (266 patients)
11 (Levi et al., 1997; Giacchetti et al., 2006), chronoFL (38 patients), or irinotecan-based
12 chronotherapy (56 patients) (Mormont et al., 2000, Gholam et al., 2006; Garufi et al., 2006).
13 Patients received a median number of 8 courses (range, 1 to 37) of the protocol that
14 immediately followed actimetry recording. Surgery for metastases resection was performed in
15 22.4 % of the patients, following this new or a subsequent chemotherapy protocol.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 ***I<O as a Prognostic Factor for Overall Survival***

34
35
36 I<O ranged from 42.3% to 100%, with a median value of 97.5%. The median OS of the
37 patients with I<O above the median value of 97.5% was 21.6 months [95% C.I., 17.8 to 25.5]
38 as compared to 11.9 months [95% C.I., 10.4 to 13.3] in the patients with I<O equal to or less
39 than 97.5% (Logrank, $p < 0.001$) (Figure 3A). The crude hazard ratios of I<O for overall
40 survival were remarkably consistent across the nine main patient characteristics subgroups,
41 including for patients with a PS of 0, 1 or 2 (Figure 4A). Results from multivariate analysis
42 thus revealed that I<O was an independent prognostic factor for overall survival, along with
43 performance status, number of metastatic sites, percentage of liver involvement, lung
44 metastases, resection of primary tumor, and number of prior chemotherapy protocols (Table
45 2). The adjusted hazard ratio corresponding to a one percent increase of I<O was 0.954 [95%
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

C.I., 0.940 to 0.968] ($p < 0.001$). Moreover the adjusted hazard ratios were remarkably similar in each of the three cohorts (Figure 4C).

I<O as a Prognostic Factor for Progression-Free Survival

The patients whose I<O value exceeded the median value of 97.5% had a median PFS of 9.3 months [95% C.I., 7.6 to 11.0], as compared to 5.8 months [4.5 to 7.1] for those with a I<O equal to or less than 97.5%. PFS curves differed significantly between both groups (Logrank, $p < 0.001$) (Figure 3B). The crude hazard ratio values were also similar in each patient subgroup categorized according to the 9 main patient characteristics, including PS (Figure 4B). The variable selection procedure retained I<O and four other prognostic factors in the best fitting Cox model (Table 2). The hazard ratio for I<O was highly statistically significant, with HR=0.970 [0.956 to 0.984], and displayed similar values in each cohort, including the Cohort III model with I<O, following forcing into the model to obtain parameter estimate and confidence interval (Figure 4D).

DISCUSSION

The rest-activity circadian rhythm was measured using the actimetry parameter I<O, which is the percentage of physical activity during the night that is less than the median activity during the day (Minors et al., 1996). This parameter was selected for this pooled analysis, since it displayed consistent prognostic value for survival in two previous studies, while mean activity and other parameters did not (Mormont et al., 2000; Innominato et al., 2009a). Here, I<O first proved to be a robust predictor of overall survival over the subsequent ten years, independent of other risk factors, in a new cohort of 142 patients with metastatic colorectal cancer. This finding is consistent with those obtained in two previous cohorts composed of colorectal cancer patients with markedly different demographic characteristics, stage of disease

Chronobiology International by F LEVI 02/05/2014

1
2 progression, and treatment protocols (Mormont et al., 2000; Innominato et al., 2009a). The
3
4 combined prediction among the 436 patients analyzed together reveals that the circadian rest-
5
6 activity rhythm measure robustly predicts overall survival. In particular, the patients with an
7
8 I<O above 97.5%, indicating relatively little nighttime activity compared to median daytime
9
10 activity, survived nearly twice as long as those with values equal to or below this value. The
11
12 prediction was not simply an indication of circadian disruption when death was imminent, but
13
14 rather a far longer-term indicator of outcome. A similar relation was statistically validated for
15
16 I<O and PFS in the pooled patient population for the first time.
17
18

19
20 Rest-activity measured with I<O is thus a sensitive measure of circadian rhythms salient to
21
22 cancer, that integrates poor sleep at night, fatigue and physical inactivity during the day, as
23
24 well as anorexia, and pain. This measure is in fact associated with all four variables, which are
25
26 under circadian control (Mormont et al., 2000, Innominato et al., Innominato et al., 2009a;
27
28 Innominato et al., 2009b). These common cancer-related problems may interact and reinforce
29
30 one another (Spiegel, 2008). This suggests the possibility that interventions designed to
31
32 improve sleep and diet and encourage physical activity have the potential to improve quantity
33
34 as well as quality of life (Butler et al., 2009 ; Palesh et al., 2007 ; Spiegel, 2011). Changes in
35
36 of I<O value primarily reflect in-bed activity, the number of minutes with activity greater than
37
38 the daytime median. Thus, changes in daytime out-of-bed activity would modestly affect the
39
40 out-of-bed median, unless being substantial and sustained. As a result, the dichotomy index
41
42 I<O is in part a measure of continuity and restfulness of sleep, and its prediction of cancer
43
44 survival integrates sleep quality into the full circadian activity rhythm. Indeed, sleep is tightly
45
46 regulated by the circadian timing system, with established links between the circadian rhythm
47
48 in core body temperature and sleep onset, as well as sleep quality (Borbely & Achermann,
49
50 1992). Recent experimental data further show that increased activity during the usual activity
51
52 span reinforces the robustness of the circadian signals arising from the pacemaker neurons in
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

1
2 the SCN (Meijer, 2011). In this context, poor I<O would indeed reflect both circadian
3
4 disruption and poor sleep.
5

6
7 It appears in particular that colorectal cancer patients with I<O score of 97.5% or less are at
8
9 substantially higher risk for disease progression and death. However, no statistical or clinical
10
11 threshold was identified in our study. Rather, I<O was a continuous predictor of both OS and
12
13 PFS, that fit the definition of a biomarker: “a characteristic that is objectively measured and
14
15 evaluated as an indicator of normal biological processes, pathogenic processes, or
16
17 pharmacologic responses to a therapeutic intervention” (Buyse et al., 2010, Wagner, 2008).
18
19 The limitations of our study relate to the fact that the prognostic value of I<O was assessed in
20
21 patients with metastatic colorectal cancer, at various stages of their metastatic disease, and on
22
23 various chemotherapy protocols, though mostly including circadian-based chronotherapy.
24
25 This study also does not rule out the hypothesis that a poor I<O could indicate a more
26
27 aggressive type of cancer. Indeed, the patients with poorest I<O values displayed significantly
28
29 higher levels of circulating TGF α , IL-6 or TNF α as compared to the patients with highest
30
31 I<O. Indeed, these cytokines can alter circadian clocks in experimental models (reviewed in
32
33 (Levi et al., 2010). Experimental circadian disruption through suprachiasmatic nuclei ablation
34
35 or chronic jet lag however accelerated cancer growth in tumor-bearing mice 3 (reviewed in
36
37 (Levi et al., 2010). In the current pooled analysis, the consistent effects of I<O in each
38
39 category of established prognostic factors and its robust and independent effect on both
40
41 survival outcomes support that circadian disruption indeed contributes to poorer survival
42
43 jointly with six other variables. The consistent effects of I<O on OS and PFS in each cohort,
44
45 as well as in each category of the nine main patient characteristics, further ruled out any
46
47 significant impact of the different chemotherapy protocols that were delivered upon the
48
49 measured effect. Conversely, the fact that 82.6% of the patients received chronotherapy
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

1
2 prevented any reliable comparative assessment of the predictive value of I<O for
3
4 chronotherapy *versus* conventional treatment delivery.
5

6
7 Recent data show that chemotherapy delivery can also disrupt the rest-activity rhythm and
8
9 result in “I<O” values equal to or below 97.5%. Interestingly, the overall survival of the
10
11 patients with such circadian disruption was shorter than those who maintained an adequate
12
13 rest-activity pattern while receiving chemotherapy (Innominato et al., 2012).
14

15
16 The feasibility of a routine assessment of this circadian biomarker at low cost is being greatly
17
18 enhanced through the integration of rest-activity recording within telemedicine platforms
19
20 aiming at improving quality of life of cancer patients at home (European InCASA project
21
22 ICT-FP7) (Levi et al., 2012). The joint detection of circadian and sleep disruption through
23
24 rest-activity monitoring and I<O quantification provides a robust indicator of the prognosis of
25
26 patients with metastatic colorectal cancer which is independent of the usual clinical or
27
28 biological prognostic measures. Interventions aiming at I<O enhancement, especially when
29
30 less than 97.5%, through concomitant increase in lively out-of-bed activity and restful in-bed
31
32 nighttime sleep, have the potential to improve overall survival, as well as progression-free
33
34 survival, systemic symptoms, and quality of life of patients with advanced cancer.
35
36
37

38 39 **Conflicts of interest**

40
41 The authors declare no conflict of interest.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

REFERENCES

Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. (2003). The role of actigraphy in the study of sleep and circadian rhythms. *Sleep*.;26:342-92.

Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA. (2008). Methodological challenges when using actigraphy in research. *Journal of pain and symptom management*.;36:191-9.

Borbely AA, Achermann P. (1992). Concepts and models of sleep regulation: an overview. *Journal of sleep research*.;1:63-79.

Butler LD, Koopman C, Neri E, Giese-Davis J, Palesh O, Thorne-Yocam KA, et al. (2009). Effects of supportive-expressive group therapy on pain in women with metastatic breast cancer. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association*.;28:579-87.

Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. (2010). Biomarkers and surrogate end points--the challenge of statistical validation. *Nature reviews Clinical oncology*.;7:309-17.

Cure H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niezgodzki G, Kwiatkowski F, et al. (2002). Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. *J Clin Oncol*.;20:1175-81.

Dibner C, Schibler U, Albrecht U. (2010). The mammalian circadian timing system: organization and coordination of central and peripheral clocks. *Annual review of physiology*.;72:517-49.

Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. (2002). Host circadian clock as a control point in tumor progression. *Journal of the National Cancer Institute*.;94:690-7.

Fu L, Pelicano H, Liu J, Huang P, Lee C. (2002). The circadian gene *Period2* plays an important role in tumor suppression and DNA damage response in vivo. *Cell*.;111:41-50.

Garufi C, Vanni B, Aschelter AM, Zappala AR, Bria E, Nistico C, et al. (2006). Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. *European journal of cancer*.;42:608-16.

Gholam D, Giacchetti S, Brezault-Bonnet C, Bouchahda M, Hauteville D, Adam R, et al. (2006). Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. *The oncologist*.;11:1072-80.

Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol*.;18:136-47.

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, et al. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. *J Clin Oncol*.;24:3562-9.

IARC-Working-Group-on-the-Evaluation-of-Carcinogenic-Risks-to-Humans. (2010). *Painting, firefighting, and shiftwork*. Lyon: WHO Press;

Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, et al. (2009a). Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. *Cancer research*.;69:4700-7.

Chronobiology International by F LEVI 02/05/2014

1
2 Innominato PF, Mormont MC, Rich TA, Waterhouse J, Levi FA, Bjarnason GA. (2009b). Circadian
3 disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative
4 therapeutic approaches. *Integrative cancer therapies*.;8:361-70.

5
6 Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, et al. (2012). Prediction of
7 overall survival through circadian rest-activity monitoring during chemotherapy for metastatic
8 colorectal cancer. *International journal of cancer Journal international du cancer*.;131:2684-92.

9
10 Jaffe CC. (2006). Measures of response: RECIST, WHO, and new alternatives. *J Clin Oncol*.;24:3245-51.

11
12 Levi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin,
13 fluorouracil, and folinic acid in metastatic colorectal cancer. *International Organization for Cancer
Chronotherapy. Lancet*.;350:681-6.

14
15 Levi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, et al. (2007). Implications of
16 circadian clocks for the rhythmic delivery of cancer therapeutics. *Advanced drug delivery
17 reviews*.;59:1015-35.

18
19 Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. (2010). Circadian timing in cancer
20 treatments. *Annual review of pharmacology and toxicology*.;50:377-421.

21
22 Levi F, Arbaud A, Dispersyn G. (2012). The European In-CASA telecare-telehealth electronic platform
23 (ICT-FP7) for the daily assessment of symptoms, weight and activity in cancer patients on
24 chronotherapy at home. *Journal of Clinical Oncology*.;30:abstr TPS9154.

25
26 Li XM, Delaunay F, Dulong S, Claustrat B, Zampera S, Fujii Y, et al. (2010). Cancer inhibition through
27 circadian reprogramming of tumor transcriptome with meal timing. *Cancer research*.;70:3351-60.

28
29 Meijer J. (2011). Does the SCN control behavioral activity levels? XII Congress of the European
30 Biological Rhythms Society; Oxford, UK.

31
32 Minors D, Akerstedt T, Atkinson G, Dahlitz M, Folkard S, Levi F, et al. (1996). The difference between
33 activity when in bed and out of bed. I. Healthy subjects and selected patients. *Chronobiol Int*.;13:27-
34 34.

34
35 Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. (2000). Marked 24-h
36 rest/activity rhythms are associated with better quality of life, better response, and longer survival in
37 patients with metastatic colorectal cancer and good performance status. *Clinical cancer research : an
38 official journal of the American Association for Cancer Research*.;6:3038-45.

39
40 Palesh OG, Collie K, Batiuchok D, Tilston J, Koopman C, Perlis ML, et al. (2007). A longitudinal study of
41 depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast
42 cancer. *Biological psychology*.;75:37-44.

43
44 Spiegel D. (2008). Losing sleep over cancer. *J Clin Oncol*.;26:2431-2.

45
46 Spiegel D. (2011). Mind matters in cancer survival. *JAMA : the journal of the American Medical
47 Association*.;305:502-3.

48
49 Wagner JA. (2008). Strategic approach to fit-for-purpose biomarkers in drug development. *Annual
50 review of pharmacology and toxicology*.;48:631-51.

51
52 Wu MW, Li XM, Xian LJ, Levi F. (2004). Effects of meal timing on tumor progression in mice. *Life
53 sciences*.;75:1181-93.

Table 1: Main characteristics of the patients in the new Cohort, as well as in updated Cohorts I and II, and in the Pooled population.

Clinical and biological characteristics				
Characteristic	Patient number (%)			
	Cohort I	Cohort II	Cohort III	Pooled population
Age (years), median (range)	59 (21-78)	60 (22-75)	60 (21-83)	59 (21-83)
Sex				
Male	115 (68.5%)	71 (56.3%)	87 (61.3%)	273 (62.6%)
Female	53 (31.5%)	55 (43.7%)	55 (38.7%)	163 (37.4%)
PS (WHO) †				
0	102 (60.7%)	67 (53.2%)	84 (59.6%)	253 (58.0%)
1	52 (31.0%)	48 (38.1%)	44 (31.2%)	144 (33.0%)
2	14 (8.3%)	11 (8.7%)	13 (9.2%)	38 (8.7%)
Unknown	0	0	1 (0.7%)	1 (0.2%)
Primary Tumor Site				
Colon	118 (70.2%)	95 (75.4%)	93 (65.5%)	306 (70.2%)
Rectum	50 (29.8%)	31 (24.6%)	49 (34.5%)	130 (29.8%)
Number of Metastatic Sites †				
None	0	1 (0.8%)	8 (5.6%)	9 (2.1%)
One	70 (41.7%)	56 (44.4%)	76 (53.5%)	202 (46.3%)
Two or more	98 (58.3%)	69 (54.8%)	58 (40.8%)	225 (51.6%)
Liver metastases †	137 (81.5%)	104 (82.5%)	103 (72.5%)	344 (78.9%)
Liver replacement by tumor †				
None	31 (18.5%)	22 (17.5%)	36 (27.5%)	89 (20.4%)
<25%	63 (37.5%)	59 (46.8%)	46 (35.1%)	168 (38.5%)
≥25%	74 (44.0%)	44 (34.9%)	49 (37.4%)	167 (38.3%)

Chronobiology International by F LEVI 02/05/2014

Unknown	0	1 (0.8%)	11 (7.7%)	12 (2.8%)
Lung metastases †	71 (42.3%)	46 (36.5%)	53 (34.6%)	170 (39.0%)
BMI				
(18.5 ; 25)	88 (52.4%)	56 (44.4%)	72 (50.7%)	216 (49.5%)
<18.5 ; >25	77 (45.8%)	70 (55.6%)	69 (48.6%)	216 (49.5%)
Unknown	3 (1.8%)	0	1 (0.7%)	4 (1.0%)
Median plasma concentration (range) †				
Carcinoembryonic antigen, mg/L	44 (1-14780)	35 (0-20932)	57 (0-36845)	44 (0-36845)
CA19.9, IU/L	214 (1-78080)	82 (1-49038)	69 (1-23361)	127 (1-78080)
Treatment History Before and After Actimetry				
<i>Before actimetry</i>				
Prior surgery for				
Primary tumor †	160 (95.2%)	107 (94.9%)	134 (94.4%)	401 (84.9%)
Metastases †	53 (31.5%)	0	59 (41.5%)	112 (25.7%)
Prior chemotherapy				
Adjuvant situation	34 (20.2%)	21 (16.7%)	43 (30.7%)	98 (22.5%)
Metastatic disease †	100 (59.5%)	4 (3.2%)	98 (69.0%)	202 (46.3%)
Number of prior chemotherapy lines for metastatic disease †				
None	68 (40.5%)	126 (100%)	44 (31.0%)	238 (54.6%)
One	56 (33.3%)	0	35 (24.6%)	91 (20.9%)
Two or more	44 (26.2%)	0	63 (44.4%)	107 (24.5%)
Prior drugs given				
5-Fluorouracil	95 (56.5%)	0	93 (65.5%)	188 (43.1%)
Oxaliplatin	3 (1.8%)	0	78 (55.0%)	81 (18.6%)
Irinotecan	9 (5.4%)	0	47 (33.1%)	56 (12.8%)
Other	24 (14.3%)	0	12 (12.7%)	36 (8.2%)

Chronobiology International by F LEVI 02/05/2014

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

<i>After actimetry</i>				
Surgery for metastases	53 (31.5%)	23 (18.3%)	20 (14.1%)	96 (22.4%)
Chemotherapy protocol				
ChronoFLO	137 (81.5%)	61 (48.4%)	68 (47.9%)	266 (61.0%)
ChronoFL	31 (18.5%)	0	7 (4.9%)	38 (8.7%)
Chrono Irinotecan ± FLO	0	0	56 (39.4%)	56 (12.8%)
FOLFOX2	0	65 (51.6%)	6 (4.3%)	71 (16.3%)
Other	0	0	5 (3.5%)	5 (1.1%)
Chronotherapy	168 (100%)	61 (48.4%)	131 (92.3%)	360 (82.6%)

19 † variables significant with p-value<0.1 in univariate Cox models for overall survival.

20
21 Treatments after actimetry measures (baseline) were not candidate variables for the final Cox
22
23 models.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Chronobiology International by F LEVI 02/05/2014

Table 2: Results from Multivariate Analyses for Overall Survival and for Progression-free survival in the Pooled Population of 436 Patients with Metastatic Colorectal Cancer

Prognostic factor	Multivariate Cox Model Stratified by Cohort		
	HR	(95 % CL)	p-value
Overall Survival			
Rest-activity rhythm (I<O)	0.954	(0.940 – 0.968)	<0.001
Performance Status			
1 vs 0	1.17	(0.92 - 1.47)	0.19
2 vs 0	3.99	(2.71 – 6.00)	<0.001
Number of metastatic sites			
Two vs one	4.49	(1.34 – 15.02)	0.015
Three or more vs one	8.92	(2.57 – 30.94)	0.001
Metastatic liver replacement			
1-24% vs none	1.22	(0.88 – 1.68)	0.23
≥25% vs none	1.58	(1.24 – 2.02)	<0.001
Lung metastases (yes vs no)	0.67	(0.51 – 0.89)	0.006
Prior chemotherapy protocols			
One vs none	1.68	(1.23 – 2.30)	0.001
Two or more vs none	2.36	(1.73 – 3.21)	<0.001
Primary tumor resected (yes vs no)	0.52	(0.35 – 0.77)	0.001
Progression-Free Survival			
Rest-activity rhythm (I<O)	0.970	(0.956 – 0.984)	<0.001

Chronobiology International by F LEVI 02/05/2014

Performance Status			<0.001
1 vs 0	1.09	(0.88 – 1.36)	0.42
2 vs 0	2.29	(1.56 – 3.37)	<0.001
Number of metastatic sites			0.03
Two vs one	1.52	(0.73 – 3.17)	
Three or more vs one	1.93	(0.92 – 4.04)	0.27
Prior chemotherapy protocols			<0.001
One vs none	1.18	(0.89 – 1.58)	0.26
Two or more vs none	1.82	(1.37 – 2.42)	<0.001
Primary tumor resected (yes vs no)	0.50	(0.34 – 0.73)	<0.001

LEGEND TO FIGURES

Figure 1: Diagram depicting the constitution of the three Cohorts and the Pooled Patient Population and the Studies they originate, whenever applicable.

Figure 2: Examples of baseline rest-activity records in two patients with metastatic colorectal cancer. Patient #1 displayed a robust circadian rest-activity pattern, with an I<O of 100%, while patient #2 had circadian disruption, with an I<O of 77.8%. Both patients #1 and #2, were 35 years old, had a WHO performance status of 0, and had received first line chemotherapy for liver-only metastases prior to entering the actimetry study. The survival of patient #1 was 37.5 months as compared to 16.6 months for patient #2.

Figure 3: Overall survival (A) and Progression-free survival (B) curves in pooled population of 436 patients according to baseline rest-activity rhythm as estimated with I<O. I<O was determined at time “0” shown on the abscissa. Survival curves are compared using Logrank test. Patients are categorized according to median I<O value of 97.5% for visualization purposes.


Chronobiology International by F LEVI 02/05/2014

Figure 4: Forest plots of I<O effects on overall survival and progression-free survival according to (A, B) main patient characteristics, and (C, D) in each cohort and in the pooled analysis.

For Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1



87x52mm (300 x 300 DPI)


Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



104x74mm (300 x 300 DPI)


view Only



89x48mm (300 x 300 DPI)

Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



103x130mm (600 x 600 DPI)